We&Win Diversification Co., Ltd. AI Stock Analysis
We&Win Diversification Co., Ltd. (4113) AI Stock Analysis
We&Win Diversification Co., Ltd.
(TPEx:4113)
The score is held down by weak financial fundamentals: a 67.5% revenue decline, a swing to a NT$100 million net loss, roughly NT$2.9 billion of cash burn, and rising leverage at about 2.3x debt-to-equity that leaves limited cushion between project delivery cycles. Technicals reinforce the caution, with the price below all key moving averages and negative MACD, though oversold RSI and Stochastic readings hint at scope for a near-term bounce. Valuation is mixed: the negative P/E provides no support, while a 6.6% dividend yield and low beta offer some appeal if the next project completions arrive on schedule. The business has shown it can deliver strong profits and cash in handover years, so the current weakness may be cyclical rather than structural, but visibility and financing risk keep the overall assessment low.
We&Win Diversification Co., Ltd. (4113) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 2.95B
- Dividend Yield
- 6.56%
- Average Volume (3M)
- 237.24K
- Price to Earnings (P/E)
- -14.8
- Beta (1Y)
- 0.28
- Revenue Growth
- -90.66%
- EPS Growth
- -196.01%
- Country
- TW
- Employees
- 35
- Sector
- General
- Sector Strength
- 55
- Industry
- Engineering & Construction
We&Win Diversification Co., Ltd. Business Overview & Revenue Model
Company Description
We & Win Diversification Co., Ltd., a company headquartered in Kaohsiung City, Taiwan, primarily focuses on the acquisition, rental, and sale of real estate properties across the island. Beyond its core property activities, the firm's operations enco...
We&Win Diversification Co., Ltd. Financial Statement Overview
Summary
Financials are weak and highly cyclical. Revenue fell about 67.5% to roughly NT$610 million and the company swung from a NT$771 million profit to a NT$100 million loss, with return on equity near -2.3%. Leverage is aggressive, with debt-to-equity climbing to about 2.3x from 1.57x as borrowings rose nearly NT$2.6 billion to fund new projects while equity eroded. Cash flow is the weakest link: operating and free cash flow were roughly -NT$2.9 billion, the largest burn in six years, funded by debt. Offsetting positives include a steady ~19.5% gross margin, near-breakeven operating profit, minimal capital spending needs, and a demonstrated ability to produce large profits and NT$2.2 billion of operating cash in delivery years such as 2024.
Income Statement
29NegativeBalance Sheet
36NegativeCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 254.94M | 610.17M | 5.72B | 518.06M | 86.53M | 1.44B |
| Gross Profit | 55.77M | 119.09M | 1.52B | 109.23M | 27.40M | 364.49M |
| EBITDA | -67.24M | 3.55M | 1.06B | -40.27M | -63.54M | 209.24M |
| Net Income | -208.23M | -100.03M | 770.81M | -145.73M | -144.21M | 133.65M |
Balance Sheet | ||||||
| Total Assets | 16.60B | 15.84B | 13.20B | 15.34B | 14.04B | 12.60B |
| Cash, Cash Equivalents and Short-Term Investments | 312.50M | 420.36M | 1.34B | 221.49M | 854.70M | 1.16B |
| Total Debt | 10.15B | 9.74B | 7.10B | 9.35B | 8.47B | 7.03B |
| Total Liabilities | 12.42B | 11.58B | 8.68B | 12.23B | 10.78B | 9.12B |
| Stockholders Equity | 4.18B | 4.27B | 4.52B | 3.11B | 3.26B | 3.49B |
Cash Flow | ||||||
| Free Cash Flow | -1.08B | -2.93B | 2.21B | -970.67M | -1.55B | 141.19M |
| Operating Cash Flow | -1.07B | -2.92B | 2.22B | -937.22M | -1.50B | 141.35M |
| Investing Cash Flow | -56.04M | -540.36M | 220.55M | 77.72M | -70.79M | -10.05M |
| Financing Cash Flow | 1.07B | 2.56B | -1.60B | 869.59M | 1.31B | 245.04M |
We&Win Diversification Co., Ltd. Peers Comparison
Overall Rating
TW:175265.4Neutral
TW:173363Neutral
TW:615048Neutral
TW:687537Underperform
TW:411337Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 65Neutral | TWD 3.01B | 14.70 | ― | 5.37% | -7.50% | -23.52% | |
| 63Neutral | TWD 2.88B | 15.13 | ― | 4.51% | -8.15% | 17.27% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 48Neutral | TWD 3.00B | 16.83 | ― | 0.97% | 3.74% | ― | |
| 37Underperform | TWD 3.27B | -9.27 | ― | ― | -69.26% | -24.53% | |
| 37Underperform | TWD 2.99B | -14.78 | ― | 6.56% | -90.66% | -196.01% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4113 | We&Win Diversification Co., Ltd. | 12.95 | -8.95 | -40.87% | |
| TW:1733 | Apex Biotechnology Corp. | 28.85 | -2.52 | -8.04% | |
| TW:1752 | Nang Kuang Pharmaceutical Co., Ltd. | 29.80 | -6.94 | -18.89% | |
| TW:6150 | Tul Corporation | 62.00 | -9.80 | -13.65% | |
| TW:6838 | Formosa Pharmaceuticals, Inc. | 21.00 | -6.30 | -23.08% | |
| TW:6875 | Pharmosa Biopharm Inc. | 25.30 | -24.70 | -49.40% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
